Rituximab

Generic Name
Rituximab
Brand Names
MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
Drug Type
Biotech
Chemical Formula
-
CAS Number
174722-31-7
Unique Ingredient Identifier
4F4X42SYQ6
Background

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication

Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
Associated Therapies
-

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

First Posted Date
2023-10-13
Last Posted Date
2024-08-20
Lead Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Target Recruit Count
324
Registration Number
NCT06082102
Locations
🇨🇳

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China

🇨🇳

Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 17 locations

RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma

First Posted Date
2023-10-03
Last Posted Date
2023-10-03
Lead Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Target Recruit Count
108
Registration Number
NCT06064344

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-11-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1130
Registration Number
NCT06047080
Locations
🇩🇪

Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany

🇺🇸

Kaiser Permanente Medical Ctr, Vallejo, California, United States

🇺🇸

St. Luke's Hospital, Chesterfield, Missouri, United States

and more 236 locations

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

First Posted Date
2023-09-21
Last Posted Date
2024-10-18
Lead Sponsor
Northside Hospital, Inc.
Target Recruit Count
25
Registration Number
NCT06046248
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT06045247
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Rescue of Nephrons With ALE.F02 (RENAL-F02)

First Posted Date
2023-09-21
Last Posted Date
2024-12-20
Lead Sponsor
Alentis Therapeutics AG
Target Recruit Count
80
Registration Number
NCT06047171
Locations
🇩🇪

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany

🇩🇪

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Germany

🇪🇸

Hospital Regional Universitario de Malaga, Malaga, Spain

and more 45 locations

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

First Posted Date
2023-09-15
Last Posted Date
2024-01-16
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
12
Registration Number
NCT06040320
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

First Posted Date
2023-08-29
Last Posted Date
2024-11-06
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT06015750
Locations
🇬🇧

Research Site, Manchester, United Kingdom

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2023-08-21
Last Posted Date
2024-06-21
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
134
Registration Number
NCT06003283
Locations
🇧🇪

Reumacentrum Genk, Genk, Limburg, Belgium

🇧🇪

ZNA Jan Palfijn, Merksem, Antwerpen, Belgium

🇧🇪

OLV Aalst, Aalst, Oost-Vlaanderen, Belgium

and more 4 locations

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

First Posted Date
2023-08-14
Last Posted Date
2024-11-08
Lead Sponsor
University of Birmingham
Target Recruit Count
210
Registration Number
NCT05991388
Locations
🇬🇧

Bristol Royal Hospital for Children, Bristol, United Kingdom

🇬🇧

Royal Manchester Children's Hospital, Manchester, United Kingdom

🇬🇧

Birmingham Children's Hospital, Birmingham, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath